US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Cruise worker 'murders newborn son on board ship': Shocked co
A cruise worker on board an Italian ship 'murdered her newborn son' as horrified co-workers raised t2024-05-21Zhang Weili Defends UFC Strawweight Title Against Brazil's Amanda Lemos
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Engineer Plays Vital Role Building Padma Bridge in Bangladesh
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
Investigators return to Long Island home of Gilgo Beach serial killing suspect
MASSAPEQUA PARK, N.Y. (AP) — Investigators returned Monday to the home of a New York architect charg2024-05-21Coffee Grown by Women of Wa Ethnic Group in SW China's Yunnan Sent as a Gift at UN
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment